• Frustrated investors want rare disease drugmaker Jazz to sell its blockbuster sleep business

    26 days ago - By Business Insider

    Several top ten shareholders at Jazz Pharmaceuticals have been pushing management to consider a sale of the drugmaker's sleep business, according to people familiar with the matter.
    Nearly 75% of Jazz's revenue comes from its narcolepsy drug Xyrem.
    Investors representing nearly 20% of Jazz's shares have held talks with the company's top executives and board since the beginning of the year to voice their views, though talks have accelerated in the last several weeks, the people said.
    These investors have also said that Jazz management and its board of directors should consider a sale of the...
    Read more ...